azd4512
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 24, 2025 (NCT07123454)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD22INHIBITOR
CD22 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07109219 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2025 | AstraZeneca, Fortrea |
| NCT07123454 | Phase 1/Phase 2 (Phase 2) | Sep 24, 2025 | AstraZeneca |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2025 |
| Fortrea | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1